The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP
Abstract Background Dupilumab significantly improves symptom control in chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with large polyps at the initiation of treatment (total polyp score (TPS) ≥ 5) have been the focus in published studies. Patients with significant burden of disease but...
Main Authors: | Nicholas J. Campion, Jonas Brugger, Aldine Tu, Victoria Stanek, Faris F. Brkic, Tina J. Bartosik, David T. Liu, Bruna S. Hoehl, Katharina Gangl, Julia Eckl-Dorna, Sven Schneider |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-09-01
|
Series: | Journal of Otolaryngology - Head and Neck Surgery |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40463-023-00663-4 |
Similar Items
-
Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA
by: T. Teeling, et al.
Published: (2024-03-01) -
Management of CRSwNP in Latin America: A multidisciplinary consensus from an expert working group
by: Jorge F. Maspero, MD, et al.
Published: (2024-03-01) -
Nasal cytology and histology in CRSwNP: Two sides of the same coin
by: Matteo Gelardi, et al.
Published: (2023-03-01) -
Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy
by: Tobias Albrecht, MD, et al.
Published: (2023-05-01) -
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR
by: Diego Bagnasco, MD PhD, et al.
Published: (2024-04-01)